Glycostem Therapeutics

About

Glycostem Therapeutics B.V. is a clinical-stage biotechnology company based in 's-Hertogenbosch, Netherlands, founded in 2007. The company specializes in developing allogeneic off-the-shelf Natural Killer (NK) cell therapies aimed at treating various cancers, including leukemia, lymphoma, and solid tumors. Glycostem utilizes a proprietary GMP-compliant platform to produce high-quality NK cells from umbilical cord blood stem cells, holding eight patent families and Orphan Drug Designations. The company's lead product, oNKord® (inaleucel), is currently in Phase II development, following successful Phase I/IIa trial results. Glycostem's pipeline includes additional NK cell therapies targeting hematological malignancies and solid tumors, with a focus on scalable, off-the-shelf solutions. The company has partnered with medac GmbH for the commercialization of oNKord® and actively participates in industry events to showcase its clinical advancements and technical expertise.